Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# march.biosciences

A clinical-stage cell-therapy company targeting challenging hematological malignancies

## Sitemaps

- [XML Sitemap](https://march.bio/sitemap.xml): Contains all public & indexable URLs for this website.

## Pages

- [HOME](https://march.bio/) - Transforming Patient Care by Unlocking New Target Spaces march.biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity of additional
- [About](https://march.bio/about/) - About Us We have assembled a team of leading cell therapy scientists and drug developers. Team Members Sarah Hein, PhD CEO, Co-Founder Linkedin-in Maksim Mamonkin, PhD Co-Founder, Chair Scientific Advisory Board Linkedin-in Malcolm Brenner, MD, PhD Co-founder Link Alice Bexon, MD Acting Chief Medical Officer Linkedin-in Nebojsa Milovic, PhD Chief Technical Officer Linkedin-in Gurpreet Ratra,
- [MB-105](https://march.bio/mb-105/) - MB-105 MB-105 is a CD5 CAR T-cell technology invented at Baylor College of Medicine. It is in the clinic for the treatment of T-cell lymphoma (TCL) and T-cell acute lymphoblastic leukemia (T-ALL). Problem Challenges Solution Publications Trial Problem Challenges Solution Trial Publications Problem T-Cell Lymphoma Although targeted and cellular immunotherapies have improved the management of
- [Pipeline](https://march.bio/pipeline/) - Pipeline march.biosciences is dedicated to revolutionizing patient care by discovering and exploiting high-impact targets for cancer immunotherapy. Our lead asset, MB-105, is designed to treat relapse/refractory T-cell malignancies, currently with no effective and curative alternative treatments Pipeline Learn more about MB-105 Bioscience Programs Learn more about MB-105 Bioscience Programs Learn more about MB-105 CAR-T Therapy
- [Ongoing Trial: NCT06534060](https://march.bio/ongoing-trial-nct06534060/) - Ongoing Trial Phase 2 Trial Details ClinicalTrials.gov ID: NCT06534060 Brief SummaryPhase 2 Trial for T-cell lymphomaMB-105 is currently being evaluated in an open-label, single-arm, multicenter Phase 2 clinical trial (NCT06534060) for patients with CD5-positive relapsed or refractory T-cell lymphoma (r/r TCL). Trial sites are currently enrolling across the continental United States. Key Inclusion RequirementsMale or
- [Clinical Trials](https://march.bio/clinical-trials/) - Clinical Trials Problem Challenges Solution Trial Publications Phase 2 Trail for T-cell Lymphoma MB-105 is currently being evaluated in an open-label, single-arm, multicenter Phase 2 clinical trial (NCT06534060) for patients with CD5-positive relapsed or refractory T-cell lymphoma (r/r TCL). Trial sites are currently enrolling across the continental United States. This trial is specifically for TCL
- [Contact](https://march.bio/contact/) - Contact You can Find Us At 7255 Helix Park AveSte 300Houston, TX 77030 Email Us info@march.bio For Career Opportunities Visit Us on LinkedIn jobs@march.bio Investors & Partners
- [News & Publications](https://march.bio/publications/) - News December 8, 2025 March Biosciences Presents Positive Interim Clinical Data from Phase 2 Trial of MB-105 CD5 CAR-T Cell Therapy at ASH 2025 Annual Meeting 100% complete response rate achieved in primary cohort with acceptable safety profile in relapsed/refractory T-cell lymphoma patients Read Article December 3, 2025 march.biosciences Announces Appointment of Gurpreet Ratra, Ph.D.,
- [FCOI Policy](https://march.bio/fcoi-policy/) - Financial Confict of Interest Policy Last updated: August 20, 2024march.biosciences Inc., Financial Conflict of Interest Policy for Research Supported by The National Institutes of HealthThe purpose of this policy is to document the requirements and responsibilities associated with identifying and managing financial conflicts of interest to safeguard the integrity of march.biosciences’ research funded by the
- [Privacy Policy](https://march.bio/privacy-policy/) - Privacy Policy Last updated: May 25, 2023This Privacy Policy describes Our policies and procedures on the collection, use and disclosure of Your information when You use the Service and tells You about Your privacy rights and how the law protects You.We use Your Personal data to provide and improve the Service. By using the Service, You agree to

## Publications

- [Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity](https://march.bio/publications_post/chimeric-antigen-receptor-induced-antigen-loss-protects-cd5-cart-cells-from-fratricide-without-compromising-on-target-cytotoxicity/)
- [Anti-tumor Efficacy and Safety of Unedited Autologous CD5.CAR T cells in Relapsed/Refractory Mature T-cell Lymphomas](https://march.bio/publications_post/anti-tumor-efficacy-and-safety-of-unedited-autologous-cd5-car-t-cells-in-relapsed-refractory-mature-t-cell-lymphomas/)
- [Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL](https://march.bio/publications_post/enhanced-anti-tumor-activity-of-cd5-car-t-cells-manufactured-with-tyrosine-kinase-inhibitors-in-patients-with-relapsed-refractory-t-all/)
- [Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies](https://march.bio/publications_post/reversible-transgene-expression-reduces-fratricide-and-permits-4-1bb-costimulation-of-car-t-cells-directed-to-t-cell-malignancies/)
- [Chimeric Antigen Receptors for T-Cell Malignancies](https://march.bio/publications_post/test-1-long-title-of-publication-and-lorem-inseam-summit-locator-forta-mar-sutur-de-en-muh/) - Our approaches combine biological and engineering insights to enable target-unlock without the risk and complexity of additional gene editing. march.biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies for challenging indications across hematological cancers. This is test copy as an example of content length. Lorem ipsum dolor sit
- [A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies](https://march.bio/publications_post/a-t-cell-directed-chimeric-antigen-receptor-for-the-selective-treatment-of-t-cell-malignancies/)
- [Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies](https://march.bio/publications_post/safety-and-anti-tumor-activity-of-cd5-car-t-cells-in-patients-with-relapsed-refractory-t-cell-malignancies/)

## News

- [March Biosciences Presents Positive Interim Clinical Data from Phase 2 Trial of MB-105 CD5 CAR-T Cell Therapy at ASH 2025 Annual Meeting](https://march.bio/news/march-biosciences-presents-positive-interim-clinical-data-from-phase-2-trial-of-mb-105-cd5-car-t-cell-therapy-at-ash-2025-annual-meeting/)
- [march.biosciences Announces Appointment of Gurpreet Ratra, Ph.D., as Chief Business Officer](https://march.bio/news/march.biosciences-announces-appointment-of-gurpreet-ratra-ph-d-as-chief-business-officer/)
- [march.biosciences Announces Oral Presentation of MB-105 Interim Phase 2 Clinical Data at American Society of Hematology Annual Meeting](https://march.bio/news/march.biosciences-announces-oral-presentation-of-mb-105-interim-phase-2-clinical-data-at-american-society-of-hematology-annual-meeting/)
- [march.biosciences Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for MB-105 in Relapsed/Refractory CD5-Positive T-Cell Lymphoma](https://march.bio/news/march.biosciences-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-mb-105-in-relapsed-refractory-cd5-positive-t-cell-lymphoma/)
- [march.biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of MB-105, First-in-Class CD5 CAR-T Cell Therapy for T-Cell Lymphoma](https://march.bio/news/march.biosciences-announces-first-patient-dosed-in-phase-2-clinical-trial-of-mb-105-first-in-class-cd5-car-t-cell-therapy-for-t-cell-lymphoma/)
- [march.biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma](https://march.bio/news/march.biosciences-receives-fda-orphan-drug-designation-for-mb-105-a-first-in-class-cd5-car-t-cell-therapy-for-t-cell-lymphoma/)
- [march.biosciences Closes Oversubscribed $28.4 Million Series A Financing](https://march.bio/news/march.biosciences-closes-oversubscribed-28-4-million-series-a-financing/)
- [Cell therapy developed by Baylor scientists shows promise as woman remains cancer-free after 5 years](https://march.bio/news/cell-therapy-developed-by-baylor-scientists-shows-promise-as-woman-remains-cancer-free-after-5-years/)
- [march.biosciences Awarded $13.4 Million by CPRIT to Advance Its CD5 CAR-T Therapy for T-cell Lymphoma in Phase 2 Trials](https://march.bio/news/march.biosciences-awarded-13-4-million-by-cprit-to-advance-its-cd5-car-t-therapy-for-t-cell-lymphoma-in-phase-2-trials/)
- [Cancer Focus Fund invests $4.8M into Houston-based march.biosciences](https://march.bio/news/cancer-focus-fund-invests-4-8m-into-houston-based-march.biosciences/)
- [The AIM-HI Accelerator Fund Recognizes, Honors, and Congratulates Its 2023 Women’s Venture Competition Top Winners](https://march.bio/news/the-aim-hi-accelerator-fund-recognizes-honors-and-congratulates-its-2023-womens-venture-competition-top-winners/)
- [march.biosciences and Cancer Focus Fund Announce $4.8 Million Investment to Support a Phase 2 Clinical Trial of Novel CAR-T Therapy for T-Cell Lymphoma](https://march.bio/news/march.biosciences-and-cancer-focus-fund-announce-4-8-million-investment-to-support-a-phase-2-clinical-trial-of-novel-car-t-therapy-for-t-cell-lymphoma/)
- [march.biosciences and CTMC Form Strategic Alliance to Propel Innovative Cancer Cell Therapies](https://march.bio/news/march.biosciences-and-ctmc-form-strategic-alliance-to-propel-innovative-cancer-cell-therapies/) - march.biosciences has forged a strategic alliance with CTMC, a joint venture between Resilience + MD Anderson Cancer Center. The partnership is focused on the development of march.biosciences' lead asset, MB-105, and advanced cellular therapy currently in clinical studies.
- [march.biosciences Welcomes Peter Olagunju to its Board of Directors](https://march.bio/news/march.biosciences-welcomes-peter-olagunju-to-its-board-of-directors/) - march.biosciences, a clinical-stage cell therapy company, proudly welcomes Peter Olagunju to its Board of Directors. Mr. Olagunju's extensive experience in driving advancements in cell and gene therapies will be invaluable as march.biosciences continues its journey of innovation and navigates the next phase of clinical development.
- [Portal Innovations to call Houston its third home, with CAR-T startup march.biosciences already in the portfolio](https://march.bio/news/portal-innovations-to-call-houston-its-third-home-with-car-t-startup-march.biosciences-already-in-the-portfolio/)
- [march.biosciences recognized as a Most Promising Life Science Company by the Greater Houston Partnership at the Texas Life Science Forum.](https://march.bio/news/march.biosciences-recognized-as-a-most-promising-life-science-company-by-the-greater-houston-partnership-at-the-texas-life-science-forum/)
- [2023 AIM-HI Women’s Venture Competition Announced Six Semi-Finalists](https://march.bio/news/2023-aim-hi-womens-venture-competition-announced-six-semi-finalists/)
- [Dr. Max Mamonkin awarded ASGCT 2023 Outstanding New Investigator](https://march.bio/news/asgct-2023-outstanding-new-investigato/) - You will not need to type anything in this location if this is a News Article. Only use this section for Press Releases. Please put your excerpt in the "Post Excerpt" below.

## Categories

- [Uncategorized](https://march.bio/category/uncategorized/)